REVIEW PAPER
HIV induced suppression of host immunity: relevance to Mycobacterium tuberculosis infections
Submission date: 2016-07-15
Final revision date: 2016-11-21
Acceptance date: 2016-12-06
Publication date: 2017-03-30
HIV & AIDS Review 2017;16(3):140-154
KEYWORDS
TOPICS
ABSTRACT
Compromised immunity among human immunodeficiency virus (HIV) infection attracts some of the most notorious opportunistic infections (OIs) like Mycobacterium tuberculosis etc. The increased burden of HIV tuberculosis (HIV-TB) cases also increases their transmission rate in the community. Chemotherapy presumably brings down the viral number below certain threshold number, which can be successfully contained by the host immune response. An impaired immunity, not only facilitates the dissemination of virus, but also fails to mount sufficient level of effector immune response to inhibit the OIs. In general, the outcome of the infection is decided by the equilibrium between the host’s effector immune response and extent of immune suppression, which facilitates immune evasion strategies evolved by the virus. During HIV infection, perturbation of immune homeostasis results from alteration in the representation of various fine T cell subsets, performing highly selective immune functions. This appears to have critical impact on effector T cell responses that keep the viral load under check and maintain latency of M. tuberculosis infection including other OIs. However, the precise role of these suppressor cells on the immune response among HIV infected individuals remains far from conclusive. Any alteration in frequency and function of these fine T cells that regulates the terminal effector response against latent M. tuberculosis infection, plausibly results in perturbation of immunity ending in reactivation of M. tuberculosis infection. The present review focuses the immunopathogenesis, immune suppression, and reactivation of M. tuberculosis among HIV infected patients.
REFERENCES (203)
2.
Zeier MD. Targeting HIV: past, present and future. Infect Disord Drug Targets 2011; 11: 98-114.
3.
Pacold M, Soto P. Retroviruses and opportunistic infections – 15th annual conference. IDrugs 2008; 11: 233-235.
5.
Borkow G, Bentwich Z. HIV and helminth co-infection: is deworming necessary? Parasite Immunol 2006; 28: 605-612.
6.
Wilkinson KA, Schwander S, Torok ME, et al. Human immunodeficiency virus-associated tuberculosis. Clin Dev Immunol 2011; 2011: 513967.
7.
Corti M, Palmero D, Eiguchi K. Respiratory infections in immunocompromised patients. Curr Opin Pulm Med 2009; 15: 209-217.
8.
Ali A. Leishmaniases and HIV/AIDS co-infections: review of common features and management experiences. Ethiop Med J 2002; 40 Suppl 1: 37-49.
9.
UNAIDS. Global AIDS Update 2016, 2016, pp. 1-12. Available at: http://www.unaids.org/en/resou...- update-2016.
10.
Verheggen R. Immune restoration in patients with HIV infection: HAART and beyond. J Assoc Nurses AIDS Care 2003; 14: 76-82.
11.
Sedaghat AR, Rastegar DA, O’Connell KA, et al. T cell dynamics and the response to HAART in a cohort of HIV-1-infected elite suppressors. Clin Infect Dis 2009; 49: 1763-1766.
12.
Feller L, Wood NH, Chikte UM, et al. Tuberculosis part 3: HIV-tuberculosis co-infection. SADJ 2009; 64: 352-354.
13.
Kalsdorf B, Scriba TJ, Wood K, et al. HIV-1 infection impairs the bronchoalveolar T-cell response to mycobacteria. Am J Respir Crit Care Med 2009; 180: 1262-1270.
14.
Westreich D, MacPhail P, Van Rie A, et al. Effect of pulmonary tuberculosis on mortality in patients receiving HAART. AIDS 2009; 23: 707-715.
15.
Lawn SD, Churchyard G. Epidemiology of HIV-associated tuberculosis. Curr Opin HIV AIDS 2009; 4: 325-333.
16.
Martinson NA, Moultrie H, van Niekerk R, et al. HAART and risk of tuberculosis in HIV-infected South African children: a multi-site retrospective cohort. Int J Tuberc Lung Dis 2009; 13: 862-867.
17.
Pawlowski A, Sköld M, Rottenberg ME, et al. Tuberculosis and HIV co-infection. PLoS Pathog 2012; 8: e1002464.
18.
Fernandez S, Lim A, French M. Immune activation and the pathogenesis of HIV disease: implications for therapy. J HIV Ther 2009; 14: 52-56.
19.
Brainard DM, Seung E, Frahm N, et al. Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice. J Virol 2009; 83: 7305-7321.
20.
Galati D, Bocchino M. New insights on the perturbations of T cell cycle during HIV infection. Curr Med Chem 2007; 14: 1920-1924.
21.
Sirois M, Robitaille L, Sasik R, et al. R5 and X4 HIV viruses differentially modulate host gene expression in resting CD4+ T cells. AIDS Res Hum Retroviruses 2008; 24: 485-493.
22.
Coiras M, Lopez-Huertas MR, Perez-Olmeda M, et al. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol 2009; 7: 798-812.
23.
Willard S, Holzemer WL, Wantland DJ, et al. Does “asymptomatic” mean without symptoms for those living with HIV infection? AIDS Care 2009; 21: 322-328.
24.
Ford ES, Puronen CE, Sereti I. Immunopathogenesis of asymptomatic chronic HIV Infection: the calm before the storm. Curr Opin HIV AIDS 2009; 4: 206-214.
25.
Huang MB, James CO, Powell MD, et al. Apoptotic peptides derived from HIV-1 Nef induce lymphocyte depletion in mice. Ethn Dis 2008; 18: S2-30-37.
26.
Yates A, Stark J, Klein N, et al. Understanding the slow depletion of memory CD4+ T cells in HIV infection. PLoS Med 2007; 4: e177.
27.
Tsong Fang HR, Colantonio AD, Uittenbogaart CH. The role of the thymus in HIV infection: a 10-year perspective. AIDS 2008; 22: 171-184.
29.
Tomaras GD, Haynes BF. HIV-1-specific antibody responses during acute and chronic HIV-1 infection. Curr Opin HIV AIDS 2009; 4: 373-379.
30.
Maslin CL, Kedzierska K, Webster NL, et al. Transendothelial migration of monocytes: the underlying molecular mechanisms and consequences of HIV-1 infection. Curr HIV Res 2005; 3: 303-317.
31.
Hasegawa A, Liu H, Ling B, et al. The level of monocyte turnover predicts disease progression in the macaque model of AIDS. Blood 2009; 114: 2917-2925.
32.
Gorry PR, Sonza S, Kedzierska K, et al. Isolation of human immunodeficiency virus type 1 from peripheral blood monocytes. Methods Mol Biol 2005; 304: 25-33.
33.
Ellery PJ, Crowe SM. Phenotypic characterization of blood monocytes from HIV-infected individuals. Methods Mol Biol 2005; 304: 343-353.
34.
Rao VR, Eugenin EA, Berman JW, et al. Methods to study monocyte migration induced by HIV-infected cells. Methods Mol Biol 2009; 485: 295-309.
35.
Yadav A, Collman RG. CNS inflammation and macrophage/microglial biology associated with HIV-1 infection. J Neuroimmune Pharmacol 2009; 4: 430-447.
36.
Alexaki A, Liu Y, Wigdahl B. Cellular reservoirs of HIV-1 and their role in viral persistence. Curr HIV Res 2008; 6: 388-400.
37.
Wang H, Sun J, Goldstein H. Human immunodeficiency virus type 1 infection increases the in vivo capacity of peripheral monocytes to cross the blood-brain barrier into the brain and the in vivo sensitivity of the blood-brain barrier to disruption by lipopolysaccharide. J Virol 2008; 82: 7591-7600.
38.
Douek DC, Roederer M, Koup RA. Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med 2009; 60: 471-484.
39.
Song XT, Aldrich M, Chen SY. Suppressor of cytokine signalling 1 inhibition strategy to enhance anti-HIV vaccination. Expert Rev Vaccines 2006; 5: 495-503.
40.
Ma W, Mishra S, Gajanayaka N, et al. HIV-1 Nef inhibits lipopolysaccharide-induced IL-12p40 expression by inhibiting JNK-activated NFkappaB in human monocytic cells. J Biol Chem 2009; 284: 7578-7587.
41.
Brockman MA, Kwon DS, Tighe DP, et al. IL-10 is up-regulated in multiple cell types during viremic HIV infection and reversibly inhibits virus-specific T cells. Blood 2009; 114: 346-356.
42.
Elrefaei M, Ventura FL, Baker CA, et al. HIV-specific IL-10-positive CD8+ T cells suppress cytolysis and IL-2 production by CD8+ T cells. J Immunol 2007; 178: 3265-3271.
43.
Hosmalin A, Lebon P. Type I interferon production in HIV-infected patients. J Leukoc Biol 2006; 80: 984-993.
44.
Pedroza-Martins L, Boscardin WJ, Anisman-Posner DJ, et al. Interferon-gamma decreases replication of primary R5 HIV-1 isolates in thymocytes. AIDS 2006; 20: 939-942.
45.
de Castro Cunha RM, Kallas EG, Rodrigues DS, et al. Interferon-gamma and tumour necrosis factor-alpha production by CD4+ T and CD8+ T lymphocytes in AIDS patients with tuberculosis. Clin Exp Immunol 2005; 140: 491-497.
46.
Lewinsohn DA, Heinzel AS, Gardner JM, et al. Mycobacterium tuberculosis-specific CD8+ T cells preferentially recognize heavily infected cells. Am J Respir Crit Care Med 2003; 168: 1346-1352.
47.
Lewinsohn DA, Winata E, Swarbrick GM, et al. Immunodominant tuberculosis CD8 antigens preferentially restricted by HLA-B. PLoS Pathog 2007; 3: 1240-1249.
48.
Havlir DV, Getahun H, Sanne I, et al. Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. JAMA 2008; 300: 423-430.
49.
Diedrich CR, O’Hern J, Wilkinson RJ. HIV-1 and the Mycobacterium tuberculosis granuloma: a systematic review and meta-analysis. Tuberculosis (Edinb) 2011; 98: 62-76.
50.
Boasso A, Vaccari M, Nilsson J, et al. Do regulatory T-cells play a role in AIDS pathogenesis? AIDS Rev 2006; 8: 141-147.
51.
Card CM, McLaren PJ, Wachihi C, et al. Decreased immune activation in resistance to HIV-1 infection is associated with an elevated frequency of CD4(+) CD25(+) FOXP3(+) regulatory T cells. J Infect Dis 2009; 199: 1318-1322.
52.
Fazekas de St Groth B, Landay AL. Regulatory T cells in HIV infection: pathogenic or protective participants in the immune response? AIDS 2008; 22: 671-683.
53.
Elrefaei M, Burke CM, Baker CA, et al. TGF-beta and IL-10 production by HIV-specific CD8+ T cells is regulated by CTLA-4 signalling on CD4+ T cells. PLoS One 2009; 4: e8194.
54.
Baba K, Sornes S, Hoosen AA, et al. Evaluation of immune responses in HIV infected patients with pleural tuberculosis by the QuantiFERON TB-Gold interferon-gamma assay. BMC Infect Dis 2008; 8: 35.
55.
Marjani M, Yousefzadeh A, Baghaei P, et al. Impact of HIV infection on tuberculous pleural effusion. Int J STD AIDS 2015; 27: 363-369.
56.
Keshinro B, Diul MY. HIV-TB: epidemiology, clinical features and diagnosis of smear-negative TB. Trop Doct 2006; 36: 68-71.
57.
Cervio JS. HIV and your immune system. How they work and why it’s important. Posit Aware 2009; 20: 17-21.
59.
Bishai WR, Chaisson RE. Opportunistic infections: down but not out. Hopkins HIV Rep 1999; 11: 2,7,12.
60.
Halsey NA, Coberly J, Chaisson R. Prevention of tuberculosis in HIV-1. Lancet 1998; 352: 742.
61.
Chaisson RE, Bishai W. No news is good news: opportunistic infections. Hopkins HIV Rep 1998; 10: 2,11.
62.
Shacklett BL, Critchfield JW, Ferre AL, et al. Mucosal T-cell responses to HIV: responding at the front lines. J Intern Med 2009; 265: 58-66.
63.
Chaudhry A, Verghese DA, Das SR, et al. HIV-1 Nef promotes endocytosis of cell surface MHC class II molecules via a constitutive pathway. J Immunol 2009; 183: 2415-2424.
64.
Chaudhry A, Das SR, Jameel S, et al. A two-pronged mechanism for HIV-1 Nef-mediated endocytosis of immune costimulatory molecules CD80 and CD86. Cell Host Microbe 2007; 1: 37-49.
65.
Chaudhry A, Das SR, Hussain A, et al. The Nef protein of HIV-1 induces loss of cell surface costimulatory molecules CD80 and CD86 in APCs. J Immunol 2005; 175: 4566-4574.
66.
Addo MM, Draenert R, Rathod A, et al. Fully differentiated HIV-1 specific CD8+ T effector cells are more frequently detectable in controlled than in progressive HIV-1 infection. PLoS One 2007; 2: e321.
67.
Kuerten S, Asaad RJ, Schoenberger SP, et al. The TRAIL of helpless CD8+ T cells in HIV infection. AIDS Res Hum Retroviruses 2008; 24: 1175-1183.
68.
De Boer RJ. Understanding the failure of CD8+ T-cell vaccination against simian/human immunodeficiency virus. J Virol 2007; 81: 2838-2848.
69.
Achour A, Biquard JM, Krsmanovic V, et al. Induction of human immunodeficiency virus (HIV-1) envelope specific cell-mediated immunity by a non-homologous synthetic peptide. PLoS One 2007; 2: e1214.
70.
Agnellini P, Wolint P, Rehr M, et al. Impaired NFAT nuclear translocation results in split exhaustion of virus-specific CD8+ T cell functions during chronic viral infection. Proc Natl Acad Sci U S A 2007; 104: 4565-4570.
71.
Ali A, Ng HL, Dagarag MD, et al. Evasion of cytotoxic T lymphocytes is a functional constraint maintaining HIV-1 Nef expression. Eur J Immunol 2005; 35: 3221-3228.
72.
Lewis MJ, Balamurugan A, Ohno A, et al. Functional adaptation of Nef to the immune milieu of HIV-1 infection in vivo. J Immunol 2008; 180: 4075-4081.
73.
Shalekoff S, Meddows-Taylor S, Gray GE, et al. Identification of human immunodeficiency virus-1 specific CD8+ and CD4+ T cell responses in perinatally-infected infants and their mothers. AIDS 2009; 23: 789-798.
74.
Sacha JB, Chung C, Rakasz EG, et al. Gag-specific CD8+ T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J Immunol 2007; 178: 2746-2754.
75.
Snyder-Cappione JE, Divekar AA, Maupin GM, et al. HIV-specific cytotoxic cell frequencies measured directly ex vivo by the Lysispot assay can be higher or lower than the frequencies of IFN-gamma-secreting cells: anti-HIV cytotoxicity is not generally impaired relative to other chronic virus responses. J Immunol 2006; 176: 2662-2668.
76.
Buseyne F, Scott-Algara D, Corre B, et al. Poor recognition of HIV-1 Nef protein by CD8 T cells from HIV-1-infected children: impact of age. Virology 2006; 354: 271-279.
77.
Doria-Rose NA, Connors M. Antibody-secreting B cells in HIV infection. Curr Opin HIV AIDS 2009; 4: 426-430.
78.
Odinsen O, Parker D, Radebe F, et al. Early detection of human immunodeficiency virus type 1-specific B-lymphocyte-derived antibodies in a high-risk population. Clin Vaccine Immunol 2009; 16: 1060-1065.
79.
Moir S, Fauci AS. B cells in HIV infection and disease. Nat Rev Immunol 2009; 9: 235-245.
80.
Banki Z, Wilflingseder D, Ammann CG, et al. Factor I-mediated processing of complement fragments on HIV immune complexes targets HIV to CR2-expressing B cells and facilitates B cell-mediated transmission of opsonized HIV to T cells. J Immunol 2006; 177: 3469-3476.
81.
Phuah JY, Mattila JT, Lin PL, et al. Activated B cells in the granulomas of nonhuman primates infected with Mycobacterium tuberculosis. Am J Pathol 2012; 181: 508-514.
82.
Alam SM, Morelli M, Dennison SM, et al. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc Natl Acad Sci USA 2009; 106: 20234-20239.
83.
Alam SM, Scearce RM, Parks RJ, et al. Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection. J Virol 2008; 82: 115-125.
84.
Balla-Jhagjhoorsingh SS, Willems B, Heyndrickx L, et al. Characterization of neutralizing profiles in HIV-1 infected patients from whom the HJ16, HGN194, and HK20 mAbs were obtained. PLoS One 2011; 6: e25488.
85.
Bonsignori M, Moody MA, Parks RJ, et al. HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection. J Immunol 2009; 183: 2708-2717.
86.
Kresge KJ. Identifying broadly neutralizing antibody activity in HIV- infected individuals. IAVI Rep 2009; 13: 18.
87.
Montgomery DL, Wang YJ, Hrin R, et al. Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41. MAbs 2009; 1: 462-474.
88.
Haynes BF, Moody MA, Verkoczy L, et al. Antibody polyspecificity and neutralization of HIV-1: a hypothesis. Hum Antibodies 2005; 14: 59-67.
89.
Srivastava IK, Ulmer JB, Barnett SW. Role of neutralizing antibodies in protective immunity against HIV. Hum Vaccin 2005; 1: 45-60.
90.
Boliar S, Murphy MK, Tran TC, et al. B-lymphocyte Dysfunction in Chronic HIV-1 Infection Does Not Prevent Cross-clade Neutralization Breadth. J Virol 2012; 86: 10.
91.
D’Souza M, Fontenot AP, Mack DG, et al. Programmed death 1 expression on HIV-specific CD4+ T cells is driven by viral replication and associated with T cell dysfunction. J Immunol 2007; 179: 1979-1987.
92.
Rosignoli G, Lim CH, Bower M, et al. Programmed death (PD)-1 molecule and its ligand PD-L1 distribution among memory CD4 and CD8 T cell subsets in human immunodeficiency virus-1-infected individuals. Clin Exp Immunol 2009; 157: 90-97.
93.
Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443: 350-354.
94.
Trautmann L, Janbazian L, Chomont N, et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 2006; 12: 1198-1202.
95.
Chiodi F. A link between immune hyperactivation of T cells during HIV-1 infection and the virus protease? AIDS 2006; 20: 769-771.
96.
Lore K, Karlsson Hedestam GB. Novel adjuvants for B cell immune responses. Curr Opin HIV AIDS 2009; 4: 441-446.
97.
Moore PL, Gray ES, Morris L. Specificity of the autologous neutralizing antibody response. Curr Opin HIV AIDS 2009; 4: 358-363.
98.
Abayneh SA, Ellmark P, Karlsson U, et al. Sensitivity of HIV type 1 primary isolates to human anti-CD40 antibody-mediated suppression is related to coreceptor use. AIDS Res Hum Retroviruses 2008; 24: 447-452.
99.
He W, Neil S, Kulkarni H, et al. Duffy antigen receptor for chemokines mediates trans-infection of HIV-1 from red blood cells to target cells and affects HIV-AIDS susceptibility. Cell Host Microbe 2008; 4: 52-62.
100.
Padmapriyadarsini GNSS C. Diagnosis & treatment of tuberculosis in HIV co-infected patients. Indian J Med Res 2011; 134: 850-865.
101.
Wanchu A. Advances in serology for diagnosing TB in the HIV infected. Indian J Chest Dis Allied Sci 2005; 47: 31-37.
102.
Simonney N, Dewulf G, Herrmann JL, et al. Anti-PGL-Tb1 responses as an indicator of the immune restoration syndrome in HIV-TB patients. Tuberculosis (Edinb) 2008; 88: 453-461.
103.
Rudnicka D, Schwartz O. Intrusive HIV-1-infected cells. Nat Immunol 2009; 10: 933-934.
104.
Balagopal A, Ray SC, De Oca RM, et al. Kupffer cells are depleted with HIV immunodeficiency and partially recovered with antiretroviral immune reconstitution. AIDS 2009; 23: 2397-2404.
105.
Azzam R, Kedzierska K, Leeansyah E, et al. Impaired complement-mediated phagocytosis by HIV type-1-infected human monocyte-derived macrophages involves a cAMP-dependent mechanism. AIDS Res Hum Retroviruses 2006; 22: 619-629.
106.
Akhtar LN, Qin H, Muldowney MT, et al. Suppressor of cytokine signalling 3 inhibits antiviral IFN-beta signalling to enhance HIV-1 replication in macrophages. J Immunol 2010; 185: 2393-2404.
107.
Ahmed N, Hayashi T, Hasegawa A, et al. Suppression of human immunodeficiency virus type 1 replication in macrophages by commensal bacteria preferentially stimulating Toll-like receptor 4. J Gen Virol 2010; 91: 2804-2813.
108.
Yadav A, Fitzgerald P, Sajadi MM, et al. Increased expression of suppressor of cytokine signalling-1 (SOCS-1): A mechanism for dysregulated T helper-1 responses in HIV-1 disease. Virology 2009; 385: 126-133.
109.
Minang JT, Trivett MT, Coren LV, et al. Nef-mediated MHC class I down-regulation unmasks clonal differences in virus suppression by SIV-specific CD8(+) T cells independent of IFN-gamma and CD107a responses. Virology 2009; 391: 130-139.
110.
Arhel N, Lehmann M, Clauss K, et al. The inability to disrupt the immunological synapse between infected human T cells and APCs distinguishes HIV-1 from most other primate lentiviruses. J Clin Invest 2009; 119: 2965-2975.
111.
Chaudhry A, Das SR, Jameel S, et al. HIV-1 Nef induces a Rab11-dependent routing of endocytosed immune costimulatory proteins CD80 and CD86 to the Golgi. Traffic 2008; 9: 1925-1935.
112.
Redford PS. The role of IL-10 in immune regulation during M. tuberculosis infection. Mucosal Immunology 2011; 4: 261-270.
113.
Srikanth P, Sridharan G, John TJ, et al. Increase in plasma IL-10 levels and rapid loss of CD4+ T cells among HIV-infected individuals in south India. Int J STD AIDS 2000; 11: 49-51.
114.
Nowroozalizadeh S, Mansson F, da Silva Z, et al. Studies on toll-like receptor stimuli responsiveness in HIV-1 and HIV-2 infections. Cytokine 2009; 46: 325-331.
115.
Brown JN, Kohler JJ, Coberley CR, et al. HIV-1 activates macrophages independent of Toll-like receptors. PLoS One 2008; 3: e3664.
116.
Lester RT, Yao XD, Ball TB, et al. Toll-like receptor expression and responsiveness are increased in viraemic HIV-1 infection. AIDS 2008; 22: 685-694.
117.
Tsang J, Chain BM, Miller RF, et al. HIV-1 infection of macrophages is dependent on evasion of innate immune cellular activation. AIDS 2009; 23: 2255-2263.
118.
Ahmed Z, Czubala M, Blanchet F, et al. HIV impairment of immune responses in dendritic cells. Adv Exp Med Biol 2012; 762: 201-238.
119.
Ahmed Z, Kawamura T, Shimada S, et al. The role of human dendritic cells in HIV-1 infection. J Invest Dermatol 2014; 135: 1225-1233.
120.
Pouliot K, Buglione-Corbett R, Marty-Roix R, et al. Contribution of TLR4 and MyD88 for adjuvant monophosphoryl lipid A (MPLA) activity in a DNA prime-protein boost HIV-1 vaccine. Vaccine 2014; 32: 5049-5056.
121.
Planes R, Ben Haij N, Leghmari K, et al. HIV-1 Tat protein activates both MyD88 and TRIF pathways to induce TNF-alpha and IL-10 in human monocytes. J Virol 2016; 90: 5886-5898.
122.
Pathak S, De Souza GA, Salte T, et al. HIV induces both a down-regulation of IRAK-4 that impairs TLR signalling and an up-regulation of the antibiotic peptide dermcidin in monocytic cells. Scand J Immunol 2009; 70: 264-276.
123.
Cassol E, Cassetta L, Rizzi C, et al. M1 and M2a polarization of human monocyte-derived macrophages inhibits HIV-1 replication by distinct mechanisms. J Immunol 2009; 182: 6237-6246.
124.
Cassetta L, Cassol E, Poli G. Macrophage polarization in health and disease. Sci World J 2011; 11: 2391-2402.
125.
Torheim EA, Ndhlovu LC, Pettersen FO, et al. Interleukin-10-secreting T cells define a suppressive subset within the HIV-1-specific T-cell population. Eur J Immunol 2009; 39: 1280-1287.
126.
Kared H, Lelievre JD, Donkova-Petrini V, et al. HIV-specific regulatory T cells are associated with higher CD4 cell counts in primary infection. AIDS 2008; 22: 2451-2460.
127.
Bergamini FB, Fagioli E, Placido R, et al. HIV-1 does not alter in vitro and in vivo IL-10 production by human monocytes and macrophages. Clin Exp Immunol 1998; 112: 7.
128.
Pauls E, Jimenez E, Ruiz A, et al. Restriction of HIV-1 replication in primary macrophages by IL-12 and IL-18 through the upregulation of SAMHD1. J Immunol 2013; 190: 4736-4741.
129.
Rodriguez-Frade JM, Munoz LM, Holgado BL, et al. Chemokine receptor dimerization and chemotaxis. Methods Mol Biol 2009; 571: 179-198.
130.
Brito A, Rigato PO, Almeida A, et al. Chemokine receptors expression on T cells and response to HAART among chronic HIV-1-infected subjects. Curr HIV Res 2008; 6: 539-543.
131.
Roe B, Coughlan S, Hassan J, et al. Elevated serum levels of interferon-gamma-inducible protein-10 in patients coinfected with hepatitis C virus and HIV. J Infect Dis 2007; 196: 1053-1057.
132.
Cinque P, Bestetti A, Marenzi R, et al. Cerebrospinal fluid interferon-gamma-inducible protein 10 (IP-10, CXCL10) in HIV-1 infection. J Neuroimmunol 2005; 168: 154-163.
133.
Kumar SB, Rice CE, Milner DA Jr, et al. Elevated cytokine and chemokine levels in the placenta are associated with in-utero HIV-1 mother-to-child transmission. AIDS 2012; 26: 685-694.
134.
Mosier DE. How HIV changes its tropism: evolution and adaptation? Curr Opin HIV AIDS 2009; 4: 125-130.
135.
Coetzer M, Nedellec R, Salkowitz J, et al. Evolution of CCR5 use before and during coreceptor switching. J Virol 2008; 82: 11758-11766.
136.
Lederman MM, Penn-Nicholson A, Cho M, et al. Biology of CCR5 and its role in HIV infection and treatment. JAMA 2006; 296: 815-826.
137.
Biancotto A, Grivel JC, Lisco A, et al. Evolution of SIV toward RANTES resistance in macaques rapidly progressing to AIDS upon coinfection with HHV-6A. Retrovirology 2009; 6: 61.
139.
Cashin K, Jakobsen MR, Sterjovski J, et al. Linkages between HIV-1 specificity for CCR5 or CXCR4 and in vitro usage of alternative coreceptors during progressive HIV-1 subtype C infection. Retrovirology 2013; 10: 98.
140.
Coffey MJ, Woffendin C, Phare SM, et al. RANTES inhibits HIV-1 replication in human peripheral blood monocytes and alveolar macrophages. Am J Physiol 1997; 272: L1025-1029.
141.
Kasama T, Yajima N, Matsukura S, et al. Macrophage inflammatory protein 1 and CCR5 as attractive therapeutic targets for HIV infection. Recent Pat Antiinfect Drug Discov 2006; 1: 275-280.
142.
Chandrasekaran P, Moore V, Buckley M, et al. HIV-1 Nef down-modulates C-C and C-X-C chemokine receptors via ubiquitin and ubiquitin-independent mechanism. PLoS One 2014; 9: e86998.
143.
Jin J, Colin P, Staropoli I, et al. Targeting spare CC chemokine receptor 5 (CCR5) as a principle to inhibit HIV-1 entry. J Biol Chem 2014; 289: 19042-19052.
144.
Kalsdorf B, Skolimowska KH, Scriba TJ, et al. Relationship between chemokine receptor expression, chemokine levels and HIV-1 replication in the lungs of persons exposed to Mycobacterium tuberculosis. Eur J Immunol 2012; 43: 540-549.
145.
Sun L, Zhang Y, Huang CX, et al. Therapeutic effect of RANTES-KDEL on inhibition of HIV-1 in CD34(+) human hematopoietic stem cells (hHSC). J Virol Methods 2008; 154: 194-199.
146.
Mavigner M, Delobel P, Cazabat M, et al. HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PLoS One 2009; 4: e7658.
147.
Savage P, Millrain M, Dimakou S, et al. Expansion of CD8+ cytotoxic T cells in vitro and in vivo using MHC class I tetramers. Tumour Biol 2007; 8: 70-76.
148.
Scriba TJ, Purbhoo M, Day CL, et al. Ultrasensitive detection and phenotyping of CD4+ T cells with optimized HLA class II tetramer staining. J Immunol 2005; 175: 6334-6343.
149.
Goulder PJ, Altfeld MA, Rosenberg ES, et al. Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J Exp Med 2001; 193: 181-194.
150.
Connick E, Mattila T, Folkvord JM, et al. CTL fail to accumulate at sites of HIV-1 replication in lymphoid tissue. J Immunol 2007; 178: 6975-6983.
151.
Dorrell L, Yang H, Ondondo B, et al. Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine. J Virol 2006; 80: 4705-4716.
152.
Benito JM, Lopez M, Soriano V. The role of CD8+ T-cell response in HIV infection. AIDS Rev 2004; 6: 79-88.
153.
Lopez A, van der Lubbe N, Sanchez-Palomino S, et al. Phenotypic and functional characteristics of HIV-specific CD8 T cells and gag sequence variability after autologous dendritic cells based therapeutic vaccine. Vaccine 2009; 27: 6166-6178.
154.
Masopust D. Developing an HIV cytotoxic T-lymphocyte vaccine: issues of CD8 T-cell quantity, quality and location. J Intern Med 2009; 265: 125-137.
155.
Rollman E, Smith MZ, Brooks AG, et al. Killing kinetics of simian immunodeficiency virus-specific CD8+ T cells: implications for HIV vaccine strategies. J Immunol 2007; 179: 4571-4579.
156.
Poccia F, Wallace M, Colizzi V, et al. Possible protective and pathogenic roles of gamma delta T lymphocytes in HIV-infections (Review). Int J Mol Med 1998; 1: 409-413.
157.
Riedel DJ, Sajadi MM, Armstrong CL, et al. Natural viral suppressors of HIV-1 have a unique capacity to maintain gammadelta T cells. AIDS 2009; 23: 1955-1964.
158.
Lehner T, Wang Y, Pido-Lopez J, et al. The emerging role of innate immunity in protection against HIV-1 infection. Vaccine 2008; 26: 2997-3001.
159.
Fenoglio D, Poggi A, Catellani S, et al. Vdelta1 T lymphocytes producing IFN-gamma and IL-17 are expanded in HIV-1-infected patients and respond to Candida albicans. Blood 2009; 113: 6611-6618.
160.
Rai AK, Thakur CP, Seth T, et al. Early activated Th-1 type and dominantly diverse natural killer T (CD3(+) CD161 (+) Valpha24(-)) cells in bone marrow among visceral leishmaniasis patients. Int J Parasitol 2011; 41: 1069-1077.
161.
Tsuji M. Glycolipids and phospholipids as natural CD1d-binding NKT cell ligands. Cell Mol Life Sci 2006; 63: 1889-1898.
163.
van der Vliet HJ, van Vonderen MG, Molling JW, et al. Cutting edge: Rapid recovery of NKT cells upon institution of highly active antiretroviral therapy for HIV-1 infection. J Immunol 2006; 177: 5775-5778.
164.
Chen N, McCarthy C, Drakesmith H, et al. HIV-1 down-regulates the expression of CD1d via Nef. Eur J Immunol 2006; 36: 278-286.
165.
Moreno-Fernandez ME, Zapata W, Blackard JT, et al. Human regulatory T cells are targets for human immunodeficiency virus (HIV) infection, and their susceptibility differs depending on the HIV type 1 strain. J Virol 2009; 83: 12925-12933.
166.
Cao W, Jamieson BD, Hultin LE, et al. Regulatory T cell expansion and immune activation during untreated HIV type 1 infection are associated with disease progression. AIDS Res Hum Retroviruses 2009; 25: 183-191.
167.
Ji J, Cloyd MW. HIV-1 binding to CD4 on CD4+CD25+ regulatory T cells enhances their suppressive function and induces them to home to, and accumulate in, peripheral and mucosal lymphoid tissues: an additional mechanism of immunosuppression. Int Immunol 2009; 21: 283-294.
168.
Kaufmann DE, Walker BD. PD-1 and CTLA-4 inhibitory cosignalling pathways in HIV infection and the potential for therapeutic intervention. J Immunol 2009; 182: 5891-5897.
169.
Mexas AM, Fogle JE, Tompkins WA, et al. CD4+CD25+ regulatory T cells are infected and activated during acute FIV infection. Vet Immunol Immunopathol 2008; 126: 263-272.
170.
Porichis F, Kaufmann DE. Role of PD-1 in HIV pathogenesis and as target for therapy. Curr HIV/AIDS Rep 2012; 9: 81-90.
171.
Bahraoui E, Briant L, Chazal N. E5564 inhibits immunosuppressive cytokine IL-10 induction promoted by HIV-1 Tat protein. Virol J 2014; 11: 214.
172.
Ben Haij N, Leghmari K, Planes R, et al. HIV-1 Tat protein binds to TLR4-MD2 and signals to induce TNF-alpha and IL-10. Retrovirology 2013; 10: 123.
173.
Clutton G, Bridgeman A, Reyes-Sandoval A, et al. Transient IL-10 receptor blockade can enhance CD8(+) T cell responses to a simian adenovirus-vectored HIV-1 conserved region immunogen. Hum Vaccin Immunother 2015; 11: 1030-1035.
174.
Ramaseri HS, Sunder S, Nagaraju RT, et al. IL-10 high producing genotype predisposes HIV infected individuals to TB infection. Hum Immunol 2012; 73: 605-611.
175.
Mihret A, Abebe M, Bekele Y, et al. Impact of HIV co-infection on plasma level of cytokines and chemokines of pulmonary tuberculosis patients. BMC Infect Dis 2014; 14: 125.
176.
Amar Singh ABD, Mohan A, Kumar Sharma P, et al. Foxp3+ Regulatory T Cells among Tuberculosis Patients: Impact on Prognosis and Restoration of Antigen Specific IFN-γ Producing T Cells. PLoS One 2012; 7: e44728.
177.
Sharma PK, Singh A, Sharma SK, et al. FoxP3+ Regulatory T Cells Suppress Effector T-Cell Function at Pathologic Site in Miliary Tuberculosis. Am J Respir Crit Care Med 2009; 179: 1061-1070.
178.
Paranjape RS. Immunopathogenesis of HIV infection. Indian J Med Res 2005; 121: 240-255.
179.
Paiardini M, Frank I, Pandrea I, et al. Mucosal immune dysfunction in AIDS pathogenesis. AIDS Rev 2008; 10: 36-46.
180.
Hu H, Fernando K, Ni H, et al. HIV envelope suppresses CD4+ T cell activation independent of T regulatory cells. J Immunol 2008; 180: 5593-5600.
181.
Muthu S, Cecelia AJ, Pulimi S, et al. C-reactive protein in HIV-infected patients – could it be a marker of immunosuppression? Clin Chim Acta 2007; 376: 246-247.
182.
Singh KK, Gray PK, Wang Y, et al. HLA alleles are associated with altered risk for disease progression and central nervous system impairment of HIV-infected children. J Acquir Immune Defic Syndr 2011; 57: 32-39.
183.
Ngandu NG, Bredell H, Gray CM, et al. CTL response to HIV type 1 subtype C is poorly predicted by known epitope motifs. AIDS Res Hum Retroviruses 2007; 23: 1033-1041.
184.
Singh P, Kaur G, Sharma G, et al. Immunogenetic basis of HIV-1 infection, transmission and disease progression. Vaccine 2008; 26: 2966-2980.
185.
Kaur G, Mehra N. Genetic determinants of HIV-1 infection and progression to AIDS: susceptibility to HIV infection. Tissue Antigens 2009; 73: 289-301.
186.
Sironi M, Biasin M, Cagliani R, et al. A common polymorphism in TLR3 confers natural resistance to HIV-1 infection. J Immunol 2012; 188: 818-823.
187.
Kader M, Wang X, Piatak M, et al. Alpha4(+) beta7(hi)CD4(+) memory T cells harbor most Th-17 cells and are preferentially infected during acute SIV infection. Mucosal Immunol 2009; 2: 439-449.
188.
Khvedelidze M, Chkhartishvili N, Abashidze L, et al. Expansion of CD3/ CD16/ CD56 positive NKT cells in HIV/ AIDS: the pilot study. Georgian Med News 2008; 165: 78-83.
189.
Vazquez E. OIs and co-infections and STDs. Staying healthy with HIV by keeping on top of bugs and such. Posit Aware 2009; 20: 22-23.
190.
Lakhashe S, Thakar M, Godbole S, et al. HIV infection in India: epidemiology, molecular epidemiology and pathogenesis. J Biosci 2008; 33: 515-525.
191.
Mehendale SM, Bollinger RC, Kulkarni SS, et al. Rapid disease progression in human immunodeficiency virus type 1-infected seroconverters in India. AIDS Res Hum Retroviruses 2002; 18: 1175-1179.
192.
Shen Y, Shen L, Sehgal P, et al. Clinical latency and reactivation of AIDS-related mycobacterial infections. J Virol 2004; 78: 14023-14032.
193.
Tossing G. Therapy of chronic hepatitis B and C and treatment options in HCV-HIV co-infection – European Conference on Infectious Diseases and Tropical Medicine. EuCID 2001, 3-6 May 2001, Leipzig. Eur J Med Res 2001; 6: 272-274.
194.
Fidel Jr PL. Candida-host interactions in HIV disease: relationships in oropharyngeal candidiasis. Adv Dent Res 2006; 19: 80-84.
195.
Samaranayake LP, Fidel PL, Naglik JR, et al. Fungal infections associated with HIV infection. Oral Dis 2002; 8 Suppl 2: 151-160.
196.
UNAIDS. Biomedical AIDS research: Recent and upcoming advances, 2016, pp. 1-30. Available at: http://www.unaids.org/en/resou....
197.
Haddow LJ, Easterbrook PJ, Mosam A, et al. Defining immune reconstitution inflammatory syndrome: evaluation of expert opinion versus 2 case definitions in a South African cohort. Clin Infect Dis 2009; 49: 1424-1432.
198.
Ahmad Khan F, Verkuijl S, Parrish A, et al. Performance of symptom-based tuberculosis screening among people living with HIV: not as great as hoped. AIDS 2014; 28: 1463-1472.
199.
Enserink M. Public health. In the HIV era, an old TB vaccine causes new problems. Science 2007; 318: 1059.
200.
Faurholt-Jepsen D, Range N, Praygod G, et al. BCG protects against tuberculosis irrespective of HIV status: a matched case-control study in Mwanza, Tanzania. Thorax 2012; 68: 288-289.
201.
Harries AD. Applying advances to the developing world for TB and HIV control. Int J Tuberc Lung Dis 2000; 4: S65-70.
202.
Hesseling AC, Jaspan HB, Black GF, et al. Immunogenicity of BCG in HIV-exposed and non-exposed infants following routine birth or delayed vaccination. Int J Tuberc Lung Dis 2015; 19: 454-462.
203.
Arbeláez MP. BCG vaccine effectiveness in preventing tuberculosis and its interaction with human immunodeficiency virus infection. Int J Epidemiol 2000; 29: 1085-1091.
Share
RELATED ARTICLE
| eISSN: | 1732-2707 |
| ISSN: | 1730-1270 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
